BRIEF: Everest Medicines advances with major licensing deal, new drug application approval
Everest Medicines Ltd. (1952.HK) last Thursday announced an exclusive licensing agreement to commercialize Micot’s MT1013 for the treatment of secondary hyperparathyroidism (SHPT), worth up to 1.24 billion yuan ($179 million).…
Recent Articles
RELATED ARTICLES
-
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK688331.SHG - Jacobio Pharma poised to turn a profit from precision cancer drugs
-
Kintor regeneration advances with new marketing partnership
9939.HK
- Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
